Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.
Identifieur interne : 003058 ( PubMed/Checkpoint ); précédent : 003057; suivant : 003059Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.
Auteurs : Zhi Liu [Japon] ; Ryuji Sakakibara ; Takeo Odaka ; Tomoyuki Uchiyama ; Tomoyuki Uchiyama ; Tatsuya Yamamoto ; Takashi Ito ; Masato Asahina ; Kazuya Yamaguchi ; Taketo Yamaguchi ; Takamichi HattoriSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Aged, Benzamides (chemistry), Benzamides (therapeutic use), Colon (drug effects), Constipation (drug therapy), Constipation (etiology), Female, Functional Laterality, Gastrointestinal Transit (drug effects), Humans, Male, Middle Aged, Morpholines (chemistry), Morpholines (therapeutic use), Parkinson Disease (complications), Serotonin 5-HT3 Receptor Agonists, Serotonin 5-HT4 Receptor Agonists, Treatment Outcome, Video Recording (methods).
- MESH :
- chemical , chemistry : Benzamides, Morpholines.
- chemical , therapeutic use : Benzamides, Morpholines.
- complications : Parkinson Disease.
- drug effects : Colon, Gastrointestinal Transit.
- drug therapy : Constipation.
- etiology : Constipation.
- methods : Video Recording.
- Aged, Female, Functional Laterality, Humans, Male, Middle Aged, Serotonin 5-HT3 Receptor Agonists, Serotonin 5-HT4 Receptor Agonists, Treatment Outcome.
Abstract
Mosapride citrate is a novel selective 5-HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride, mosapride does not block K(+) channels or D2 dopaminergic receptors. The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women; mean age, 67 years) with constipation (10 with bowel movement < 3 times/week; 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre- and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had a worsening of parkinsonism or other adverse events. Thirteen patients reported subjective improvements in bowel frequency (>3 times/week, 13) and difficult defecation (13). Mosapride shortened CTT of the left colon (P < 0.01) and the total colon (P < 0.05). During rectal filling, mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude in rectal contraction (P < 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects.
DOI: 10.1002/mds.20387
PubMed: 15719424
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15719424Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.</title><author><name sortKey="Liu, Zhi" sort="Liu, Zhi" uniqKey="Liu Z" first="Zhi" last="Liu">Zhi Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba 260-8670</wicri:regionArea><wicri:noRegion>Chiba 260-8670</wicri:noRegion></affiliation></author><author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name></author><author><name sortKey="Odaka, Takeo" sort="Odaka, Takeo" uniqKey="Odaka T" first="Takeo" last="Odaka">Takeo Odaka</name></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name></author><author><name sortKey="Yamamoto, Tatsuya" sort="Yamamoto, Tatsuya" uniqKey="Yamamoto T" first="Tatsuya" last="Yamamoto">Tatsuya Yamamoto</name></author><author><name sortKey="Ito, Takashi" sort="Ito, Takashi" uniqKey="Ito T" first="Takashi" last="Ito">Takashi Ito</name></author><author><name sortKey="Asahina, Masato" sort="Asahina, Masato" uniqKey="Asahina M" first="Masato" last="Asahina">Masato Asahina</name></author><author><name sortKey="Yamaguchi, Kazuya" sort="Yamaguchi, Kazuya" uniqKey="Yamaguchi K" first="Kazuya" last="Yamaguchi">Kazuya Yamaguchi</name></author><author><name sortKey="Yamaguchi, Taketo" sort="Yamaguchi, Taketo" uniqKey="Yamaguchi T" first="Taketo" last="Yamaguchi">Taketo Yamaguchi</name></author><author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20387</idno><idno type="RBID">pubmed:15719424</idno><idno type="pmid">15719424</idno><idno type="wicri:Area/PubMed/Corpus">003145</idno><idno type="wicri:Area/PubMed/Curation">003145</idno><idno type="wicri:Area/PubMed/Checkpoint">003058</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.</title><author><name sortKey="Liu, Zhi" sort="Liu, Zhi" uniqKey="Liu Z" first="Zhi" last="Liu">Zhi Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba 260-8670</wicri:regionArea><wicri:noRegion>Chiba 260-8670</wicri:noRegion></affiliation></author><author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name></author><author><name sortKey="Odaka, Takeo" sort="Odaka, Takeo" uniqKey="Odaka T" first="Takeo" last="Odaka">Takeo Odaka</name></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name></author><author><name sortKey="Yamamoto, Tatsuya" sort="Yamamoto, Tatsuya" uniqKey="Yamamoto T" first="Tatsuya" last="Yamamoto">Tatsuya Yamamoto</name></author><author><name sortKey="Ito, Takashi" sort="Ito, Takashi" uniqKey="Ito T" first="Takashi" last="Ito">Takashi Ito</name></author><author><name sortKey="Asahina, Masato" sort="Asahina, Masato" uniqKey="Asahina M" first="Masato" last="Asahina">Masato Asahina</name></author><author><name sortKey="Yamaguchi, Kazuya" sort="Yamaguchi, Kazuya" uniqKey="Yamaguchi K" first="Kazuya" last="Yamaguchi">Kazuya Yamaguchi</name></author><author><name sortKey="Yamaguchi, Taketo" sort="Yamaguchi, Taketo" uniqKey="Yamaguchi T" first="Taketo" last="Yamaguchi">Taketo Yamaguchi</name></author><author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Benzamides (chemistry)</term><term>Benzamides (therapeutic use)</term><term>Colon (drug effects)</term><term>Constipation (drug therapy)</term><term>Constipation (etiology)</term><term>Female</term><term>Functional Laterality</term><term>Gastrointestinal Transit (drug effects)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Morpholines (chemistry)</term><term>Morpholines (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Serotonin 5-HT3 Receptor Agonists</term><term>Serotonin 5-HT4 Receptor Agonists</term><term>Treatment Outcome</term><term>Video Recording (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Benzamides</term><term>Morpholines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Benzamides</term><term>Morpholines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Colon</term><term>Gastrointestinal Transit</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Constipation</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Constipation</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Video Recording</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Functional Laterality</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Serotonin 5-HT3 Receptor Agonists</term><term>Serotonin 5-HT4 Receptor Agonists</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mosapride citrate is a novel selective 5-HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride, mosapride does not block K(+) channels or D2 dopaminergic receptors. The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women; mean age, 67 years) with constipation (10 with bowel movement < 3 times/week; 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre- and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had a worsening of parkinsonism or other adverse events. Thirteen patients reported subjective improvements in bowel frequency (>3 times/week, 13) and difficult defecation (13). Mosapride shortened CTT of the left colon (P < 0.01) and the total colon (P < 0.05). During rectal filling, mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude in rectal contraction (P < 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15719424</PMID><DateCreated><Year>2005</Year><Month>06</Month><Day>06</Day></DateCreated><DateCompleted><Year>2005</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.</ArticleTitle><Pagination><MedlinePgn>680-6</MedlinePgn></Pagination><Abstract><AbstractText>Mosapride citrate is a novel selective 5-HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride, mosapride does not block K(+) channels or D2 dopaminergic receptors. The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women; mean age, 67 years) with constipation (10 with bowel movement < 3 times/week; 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre- and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had a worsening of parkinsonism or other adverse events. Thirteen patients reported subjective improvements in bowel frequency (>3 times/week, 13) and difficult defecation (13). Mosapride shortened CTT of the left colon (P < 0.01) and the total colon (P < 0.05). During rectal filling, mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude in rectal contraction (P < 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects.</AbstractText><CopyrightInformation>(c) 2005 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakakibara</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Odaka</LastName><ForeName>Takeo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Uchiyama</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Uchiyama</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Asahina</LastName><ForeName>Masato</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Taketo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Takamichi</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009025">Morpholines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058827">Serotonin 5-HT3 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058828">Serotonin 5-HT4 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>I8MFJ1C0BY</RegistryNumber><NameOfSubstance UI="C062720">mosapride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003106">Colon</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003248">Constipation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007839">Functional Laterality</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005772">Gastrointestinal Transit</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009025">Morpholines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D058827">Serotonin 5-HT3 Receptor Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D058828">Serotonin 5-HT4 Receptor Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014741">Video Recording</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20387</ArticleId><ArticleId IdType="pubmed">15719424</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Asahina, Masato" sort="Asahina, Masato" uniqKey="Asahina M" first="Masato" last="Asahina">Masato Asahina</name><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name><name sortKey="Ito, Takashi" sort="Ito, Takashi" uniqKey="Ito T" first="Takashi" last="Ito">Takashi Ito</name><name sortKey="Odaka, Takeo" sort="Odaka, Takeo" uniqKey="Odaka T" first="Takeo" last="Odaka">Takeo Odaka</name><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><name sortKey="Yamaguchi, Kazuya" sort="Yamaguchi, Kazuya" uniqKey="Yamaguchi K" first="Kazuya" last="Yamaguchi">Kazuya Yamaguchi</name><name sortKey="Yamaguchi, Taketo" sort="Yamaguchi, Taketo" uniqKey="Yamaguchi T" first="Taketo" last="Yamaguchi">Taketo Yamaguchi</name><name sortKey="Yamamoto, Tatsuya" sort="Yamamoto, Tatsuya" uniqKey="Yamamoto T" first="Tatsuya" last="Yamamoto">Tatsuya Yamamoto</name></noCountry><country name="Japon"><noRegion><name sortKey="Liu, Zhi" sort="Liu, Zhi" uniqKey="Liu Z" first="Zhi" last="Liu">Zhi Liu</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003058 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003058 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15719424
|texte= Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15719424" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |